Viralytics

Viralytics was an Australian biotechnology company focused on oncolytic virotherapy, an approach that uses viruses designed or selected to preferentially infect and destroy cancer cells while also stimulating an immune response against tumors. Its principal development product was Cavatak, the company name for a preparation of wild-type Coxsackievirus A21, a naturally occurring virus associated with mild respiratory infection. The scientific foundation for Viralytics originated at the University of Newcastle in Australia. Around 1999, virologist Darren Shafren and colleagues identified evidence that Coxsackievirus A21 could act as an oncolytic agent. Their work indicated that the virus could exploit receptors such as intercellular adhesion molecule 1 (ICAM-1), with decay-accelerating factor (DAF) acting as a co-receptor, to enter susceptible cells. Because a number of tumor types can express these molecules at elevated levels, the research suggested a possible route for selectively targeting malignant tissue. Shafren sought patent protection for the oncology application, and the University of Newcastle formed ViroTarg Pty Ltd as a spin-out to develop the technology. The project became a corporate development program when ASX-listed Psiron began funding ViroTarg in 2004. In December 2006, Psiron acquired the relevant intellectual property and changed its name to Viralytics, signaling a shift toward oncolytic-virus development as its core business. The company subsequently advanced Cavatak through preclinical studies and early clinical trials in melanoma and other cancers. In December 2005, the product received Orphan Drug designation in the United States for advanced melanoma, a regulatory recognition intended for therapies addressing serious diseases affecting relatively small patient populations; the designation did not constitute marketing approval. Cavatak's proposed therapeutic effect had two related components. First, direct viral replication could cause lysis of tumor cells. Second, infection and tumor-cell destruction could generate local inflammation and expose tumor antigens, potentially recruiting an immune response against both treated lesions and distant, untreated metastases. This made the product relevant to combination strategies involving immune checkpoint inhibitors. An early Phase I melanoma study administered Cavatak by intratumoral injection to nine patients with stage IV disease. The study produced indications of tumor-volume reduction or stabilization in several patients, although it did not establish objective responses under conventional response criteria. Viralytics then conducted the Phase II CALM study in advanced melanoma. The open-label trial evaluated 57 patients who received repeated intratumoral injections over an 18-week period. Reported results included six-month immune-related progression-free survival, one-year overall survival, complete and partial responses, and evidence of activity in some non-injected lesions. These findings supported the company's effort to investigate Cavatak in additional cancers and in combination with checkpoint inhibitors. The development program expanded into bladder cancer, non-small-cell lung cancer, prostate cancer and combination regimens involving pembrolizumab, ipilimumab and mitomycin C. The company also pursued studies examining immune changes in treated and untreated lesions. In 2015, Viralytics entered a clinical collaboration with Merck & Co. involving Cavatak and Keytruda (pembrolizumab) in lung and bladder cancer. Merck later acquired Viralytics in 2018, making it a wholly owned subsidiary and ending the company's independent public-company status. Cavatak remained an investigational therapy rather than an approved commercial medicine in the publicly described development history.

Viralytics developed from academic virology research at the University of Newcastle in New South Wales. Around 1999, a group led by Professor Darren Shafren investigated Coxsackievirus A21 and established that the virus could preferentially infect and destroy certain cancer cells. The work connected viral entry with tumor-associated expression of ICAM-1 and the co-receptor DAF. Shafren pursued patent protection for the oncology use of the virus, and the university created ViroTarg Pty Ltd to commercialize the intellectual property. In June 2004, the ASX-listed biotechnology company Psiron began funding the ViroTarg project. Psiron acquired the ViroTarg intellectual property in December 2006 and changed its corporate name to Viralytics. The new identity reflected the company's focus on oncolytic viruses rather than its earlier business orientation. The company called its Coxsackievirus A21 preparation Cavatak and developed it as an investigational treatment for cancer. Preclinical publications reported activity in melanoma and subsequently described potential activity in multiple myeloma, prostate cancer and breast cancer. These studies were based in part on the observation that susceptible tumor cells could express higher levels of viral entry molecules than normal cells. Viralytics' therapeutic theory involved both direct oncolysis and immune activation: viral replication could rupture tumor cells, while the resulting inflammation could help the immune system recognize and attack malignant cells. The first notable clinical work involved patients with advanced melanoma. A Phase I study initiated in 2007 evaluated intratumoral administration in nine stage IV melanoma patients. Results later reported by the company indicated temporary tumor-volume reductions or stabilization in several patients, but no objective responses under the study's conventional criteria. The findings nevertheless supported continued development and investigation of immune effects. Viralytics then conducted CALM, an open-label Phase II study known as CAvatak in Late Stage Melanoma. The study evaluated 57 patients with stage IIIc or stage IV melanoma. Participants received ten intratumoral injections over 18 weeks, and outcomes were assessed using immune-related response measures as well as conventional survival and response endpoints. The company reported six-month immune-related progression-free survival in a subset of patients, a one-year overall survival rate of 73 percent, an overall response rate of 28 percent, and durable responses in a smaller group. Activity was also observed in some distant, non-injected lesions, an observation consistent with the proposed systemic immune component of treatment. These were trial results, not evidence of regulatory approval or established clinical effectiveness. Development expanded through extension and combination studies. The CALM extension study examined tumor biopsies and immune changes after additional Cavatak treatment. Other programs investigated intravenous dosing in treatment-resistant cancers, intravesical or local treatment in non-muscle-invasive bladder cancer, and combinations with the checkpoint inhibitors pembrolizumab and ipilimumab. In 2015, Viralytics and Merck agreed to study Cavatak with Keytruda in lung and bladder cancer. Merck subsequently acquired Viralytics in 2018. After the acquisition, Viralytics no longer operated as an independent listed biotechnology company.

• 2018

  Merck acquired Viralytics

  [1]Viralyticsen.wikipedia.org

  Viralytics became a wholly owned subsidiary of Merck & Co.

• 2015

  CALM final data were reported

  [1]Viralyticsen.wikipedia.org

  Reported final study data included overall survival, response and durable-response findings in 57 advanced-melanoma patients.

• 2012

  The CALM Phase II melanoma study began dosing

  [1]Viralyticsen.wikipedia.org

  Cavatak entered the CALM study in patients with advanced melanoma under an Investigational New Drug framework.

• 2007

  Cavatak entered Phase I melanoma testing

  [1]Viralyticsen.wikipedia.org

  The product began clinical evaluation through intratumoral treatment of patients with advanced melanoma.

• 2006

  Psiron acquired ViroTarg intellectual property and became Viralytics

  [1]Viralyticsen.wikipedia.org

  Psiron acquired the ViroTarg technology and renamed itself Viralytics to emphasize oncolytic-virus development.

• 2005

  Cavatak received Orphan Drug designation

  [1]Viralyticsen.wikipedia.org

  The investigational product received Orphan Drug status for advanced melanoma.

• 2004

  Psiron began funding the ViroTarg project

  [1]Viralyticsen.wikipedia.org

  ASX-listed biotech company Psiron began supporting development of the University of Newcastle spin-out's oncolytic-virus intellectual property.

• 1999

  Academic discovery of Coxsackievirus A21's oncolytic potential

  [1]Viralyticsen.wikipedia.org

  A University of Newcastle team led by Darren Shafren identified evidence that Coxsackievirus A21 could preferentially infect and kill cancer cells.

A specialist oncology biotechnology company centered on oncolytic virotherapy and the potential combination of tumor-selective viral infection with immune-mediated cancer treatment.

• Oncolytic virus therapy

  Cavatak

  Cavatak was Viralytics' trade name for a preparation of wild-type Coxsackievirus A21. It was investigated as an intratumoral, intravenous and combination cancer treatment. The proposed mechanism involved viral entry into susceptible tumor cells through ICAM-1 and DAF, replication inside those cells, tumor-cell lysis and secondary stimulation of antitumor immunity. Clinical programs examined melanoma, bladder cancer, non-small-cell lung cancer and other malignancies, including combinations with pembrolizumab and ipilimumab. Cavatak remained an investigational product in the described development history.

• 2018

  Merck acquired ViralyticsM&A

  Background

  Merck had previously collaborated with Viralytics on Cavatak and pembrolizumab studies.

  Action taken

  Merck & Co. acquired the company and made it a wholly owned subsidiary.

  Aftermath

  Viralytics ceased to operate as an independent listed company, while its oncolytic-virus program moved into Merck's corporate structure.

  Source

• 2015

  Viralytics pursued checkpoint-inhibitor combinationsStrategy

  Background

  Clinical observations suggested that Cavatak could alter the tumor microenvironment and potentially complement immune checkpoint blockade.

  Action taken

  Viralytics entered a collaboration with Merck to study Cavatak with pembrolizumab in lung and bladder cancer.

  Aftermath

  The collaboration broadened Cavatak's development strategy from monotherapy toward combination immuno-oncology studies.

  Source

• 2006

  Psiron adopted the Viralytics identityStrategy

  Background

  After acquiring the ViroTarg intellectual property, Psiron made oncolytic viruses its central development focus.

  Action taken

  The company changed its name to Viralytics.

  Aftermath

  The renamed company concentrated its pipeline and corporate positioning on Cavatak and related oncolytic-virus research.

  Source

• 2018

  Merck acquired Viralytics[1]Viralyticsen.wikipedia.org

  M&A

  Merck & Co. acquired Viralytics, making the Australian oncolytic-virus developer a wholly owned subsidiary and ending its independent corporate existence.

• 2015

  Viralytics and Merck announced a Cavatak-Keytruda clinical collaboration[1]Viralyticsen.wikipedia.org

  M&A · Product launch

  The companies agreed to study Cavatak in combination with pembrolizumab in patients with lung and bladder cancers within the STORM development program.

• 2005

  Cavatak received Orphan Drug designation for advanced melanoma[1]Viralyticsen.wikipedia.org

  Regulation

  The investigational Cavatak program received Orphan Drug status for advanced melanoma. The designation recognized the disease area and development program but was not a marketing authorization.

1. 1Viralyticsen.wikipedia.org